ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 59.6% in April

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 533,000 shares, a decrease of 59.6% from the March 31st total of 1,320,000 shares. Approximately 6.1% of the company’s shares are short sold. Based on an average trading volume of 946,600 shares, the short-interest ratio is presently 0.6 days.

ABVC BioPharma Stock Down 10.7 %

ABVC BioPharma stock opened at $1.42 on Friday. ABVC BioPharma has a 52-week low of $0.67 and a 52-week high of $9.60. The firm has a fifty day moving average of $1.21 and a 200-day moving average of $1.25. The firm has a market capitalization of $15.00 million, a P/E ratio of -0.58 and a beta of 0.75.

ABVC BioPharma (NASDAQ:ABVC) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative return on equity of 226.65% and a negative net margin of 6,919.08%.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.